OR WAIT 15 SECS
The Biosimilars Forum launched Partnership for Biosimilars Education and Access, an education initiative raising awareness of biosimilars in the US.
The Biosimilars Forum, a nonprofit organization focused on expanding patient access to biosimilars in the United States, announced on Feb. 1, 2016 the launch of a new biosimilars education initiative. The initiative, Partnership for Biosimilars Education and Access, will focus on raising awareness and encouraging access to biosimilars in the US.
The Forum released two educational guides designed for healthcare professionals, media, and patient advocacy organizations to learn more about biosimilars. The tools provide background, insights, FAQs, and resources on biosimilars that can be used by multiple stakeholders. The information is available at biosimilarsforum.org.â¨â¨
"We know that some of the most difficult diseases that afflict people in the US are best treated with biological medicines," said Juliana Reed, president of the Biosimilars Forum, in a press announcement. "The introduction of biosimilars is anticipated to help drive lower cost burdens for the US healthcare system. It will also help expand earlier, more consistent access to these important medicines for patients with cancer, anemia, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, psoriasis, and Crohn's and other inflammatory bowel diseases."â¨â¨
FDA approved the first biosimilar in 2015, and more than 50 biosimilars are in development in the US. Biosimilars are approved by FDA based on the totality of evidence and on extensive comparisons to the reference product, including detailed analytical and biological assays, followed by nonclinical and pharmacokinetic/pharmacodynamic studies and then confirmation in a clinical setting.
Source: Biosimilars Forum